Abstract
The discovery that DNA sequence variations can influence the response of an individual to a drug or can predict the outcome of a disease has added a new dimension to evidence-based medicine. It is clear that the goals, risks, and benefits of drug therapy can be better assessed if the underlying genome of the patient is known. The relevance of identifying patients at increased risk of adverse drug reactions, the application of genomic technologies to drug development and the clarification of the mechanisms of drug action on cells will be important targets in the therapeutic approach to medicine in the 21st century. In this review, we summarize the development of single nucleotide polymorphisms (SNPs) and give computational biological data for SNPs databases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
